Comparison of One-Year Survival After Acute Coronary Syndrome in Patients ≥75 Years of Age With Versus Without Living With Spouse.

Patients with acute coronary syndrome (ACS) face high postevent mortality. This study aims to evaluate the impact of living without spouse on 1-year mortality of ACS patients. This retrospective study enrolled a total of 600 consecutive patients (≥75 years of age) with ACS hospitalized in our hospital between January 2013 and December 2016. Patients' clinical characteristics, laboratory values, hospital course, demographic characteristics, and angiographic data were collected. Patients were divided into 2 groups according to living with (n = 396) or without (n = 204) spouse. Patients living without spouse were older (79 [77,82] vs 77 [76,80], p <0.001), more frequently female (54.9% vs 31.8%, p <0.001), less smokers (23.5% vs 38.9%, p <0.001), lower left ventricular ejection fraction value (52.1±10.7% vs 54.4±9.8%, p = 0.021) compared with patients living with spouse. In addition, compared to patients living with spouse, patients living without spouse were less likely to get percutaneous coronary intervention (41.2% vs 54.0%, p = 0.003) during hospitalization and had higher 1-year mortality post-ACS (22.1% vs 13.4%, p = 0.006). Multivariate logistic regression analysis showed that living without spouse remained an independent risk factor for 1-year mortality after ACS in patients ≥75 years (odds ratio 2.350, 95% confidence interval 1.245 to 4.434, p = 0.008), after adjusted with age, gender, heart rate, systolic blood pressure, left ventricular ejection fraction value at baseline, hemoglobin, white blood cell, alanine aminotransferase, albumin, creatinine, brain natriuretic peptide, type of ACS, severe heart failure at admission, percutaneous coronary intervention treatment, ß blocker, diuretics application during hospital. In conclusion, living without spouse is an independent risk factor for 1-year all-cause mortality in ACS patients ≥75 years.

Oxaliplatin combined with vinorelbine in drug resistant non-small-cell lung cancer / 中国癌症杂志

Purpose: To observe the efficacy and the side effects of oxaliplatin( OXA) in combination with vinorelbine (VRB) in the treatment of drug resistant non-small-cell lung cancer( NSCLC) . Methodii: Thirty-five patients with drug resistant lung cancer were treated by OXA + VRB. OXA 100 mg/m2, VRB 25 mg/m , on d 1, which were given by bronchial arteries injection, and VRB 25mg/m2 was given by venous injection on d 8. One cycle was given every 3 weeks and total six cycles was given. Results: There was 1 patient who showed completed remission( CR), 14 patients showed partial remission( PR), 13 patients showed stable disease( SD) and 7 patients showed progress disease( PD) after the sixth cycle. The response rate was 42. 9%. The major toxicities were peripheral sensory neuropathy and leukopenia. Conclusions: The regimen of OXA plus VRB is effective on drug resistant and advanced NSCLC and the side effects are tolerable. There is higher response rate and lower neurotoxicity when the medicines are given by arterial injection than by venous injection.